For example, our lab has previously demonstrated how decreasing the levels of S1P by inhibiting sphingosine kinase-1 can be combined with anti-PD-1 therapy to produce an enhanced anti-tumor response in preclinical models [34]. This evidence concerns the gene SPHK1 and neoplasm.